You are here

Home » Content

Yüksek doz kemoterapi, otolog kemik iliği veya periferik stem cell transplantasyonu yapılacak non-Hodgkin lenfomalı hastalarda fitohemaglutinin'e cevabın araştırılması

The Investigation of the Responses to Phytohemagglutinin in the Patients of non-Hodgkin's Lymphoma who were Candidates for High Dose Chemotherapy, Autologous Bone Marrow, or Peripheral Stem Cell Transplantation

Journal Name:

  • İnönü Üniversitesi Tıp Fakültesi Dergisi

Publication Year:

  • 1996

Key Words:

Keywords (Original Language):

Author NameUniversity of Author
Abstract (2. Language): 
Phytohemagglutinin (PHA) is principally a T lymphocyte mitogen, producing a greater stimulatory effect on CD4+ helper/inducer T lymphocytes than on CD8+ suppressor/cytotoxic T cells. In this study, we investigated if there are differences in the mitogenic response to PHA between autologous bone marrow (BM) and granulocyte-monocyte colony stimulating factor (GM-CSF)-mobilized peripheral stem cell (PSC) products as well as to normal peripheral blood leukocytes (PBL). BM and PSC products from 24 patients with non-Hodgkin's lymphoma (NHL) were collected and assays of cell proliferation in response to PHA were performed both before and following 5 days co-incubation with IL-2. The proliferative response to PHA by cells from both PSC and BM products were significantly lower than normal PBL (p<0.001). The PHA response of PSC was significantly higher than that observed with BM (p<0.01). The response to PHA of PSC was higher than BM (p<0.05). When compared before culture with IL-2, the PHA response of PBL was decreased (p<0.05), but PSC and BM was not changed. This study showed that the PSC products prior to IL-2 incubation had higher mitogenic response to PHA. According to these results the depressed mitogenic response of lymphocytes from non-Hodgkin patients was associated with an increase in "baseline" proliferation due to membrane bound IL-2 resulting in continued proliferation. [Journal of Turgut Özal Medical Center 1996;3(4):306-310]
Bookmark/Search this post with
Abstract (Original Language): 
Fitohemaglutinin (PHA), genellikle bir T lenfosit mitojenidir. CD4+ helper/inducer T lenfositlerine, CD8+ suppressor/cytotoxic T lenfositlerine göre daha fazla stimulator etki yapar. Bu çalışmada, biz normal periferik kan lökositleri (PBL) ile otolog kemik iliği (BM) ve granulosit-monosit koloni stimulan faktör (GM-CSF) ile mobilize edilmiş periferik stem cell (PSC) ürünlerinin PHA 'e verdikleri mitojenik cevapların farklı olup olmadığını araştırdık Non-Hodgkin lenfomalı 24 hastadan kemik iliği ve periferik stem cell ürünleri toplandı ve IL-2 ile 5 gün kültür yapılmadan önce ve yapıldıktan sonra PHA hücre proliferasyon cevabı incelendi. Hem PSC hem de BM hücrelerinin PHA proliferatif cevapları anlamlı şekilde normal PBL 'den düşüktü (p<0.01). PSC'in PHA cevabı BM'unkinden daha yüksekti (p<0.05). IL-2 ile kültür yapıldıktan sonra PBL'nin PHA cevabı azaldı (p<0.05) fakat PSC ve BM'unki değişmedi. Bu çalışma sonucunda IL-2 ile inkübasyona PSC ürünleri PHA'e daha yüksek mitojenik cevap verdi. Bu sonuçlara göre non-Hodgkin lenfomalı hastaların lenfositlerindeki deprese mitojenik cevap, membrana bağlı IL-2 'nin sürekli stimüle olması nedeniyle yüksek baz proliferasyona sebep olduğunu düşündürmektedir. [Turgut Özal Tıp Merkezi Dergisi 1996;3(4):306-310]
FULL TEXT (PDF): 
PDF icon arastirmax-yuksek-doz-kemoterapi-otolog-kemik-iligi-periferik-stem-cell-transplantasyonu-yapilacak-non-hodgkin-lenfomali-hastalarda-fitohemaglutinine-cevabin-arastirilmasi.pdf
  • 4
306-310
  • Turkish

REFERENCES

References: 

1. Cruise JM, Lewis RE. Illustrated Dictionary of Immunology. New York. CRC press. 1995:206.
2. Oppenheim JJ, Ruscetti FW, Faltynek C. Cytockines. In: Stites DP, Terr AI, Parslow TG, (eds). Basic and Clinical Immunology. 8th ed. Norwalk. Appleton and Lange. 1994:105-23.
3. Gibson FM, Malkovska V, Myint AA, et al. Mechanism of suppression of normal hematopoietic activity by lymphokine-activated killer cells and their products. Exp Hematol 1991; 19:659-73.
4. Lum LG. The kinetics of immune reconstitution after human marrow transplantation. Blood 1987; 69:369-80.
5. Lum LG, Ueda M. Immunodeficiency and the role of suppressor cells after human bone marrow transplantation. Clin Immunol Immunopathol 1992; 63:103-9.
6. Gottschalk LR, Bray RA, Kaizer H, Gebel HM. Two populations of CD56 (Leu-19)+ /CD16+ cells in bone marrow transplant recipients. Bone Marrow Transplant
1990; 5:259-64.
7. Talmadge JE, Reed EC, Kessinger A, et al. Immunologic attributes of cytockine mobilized peripheral blood stem cells and recovery following transplantation in non-Hodgkin's lymphoma patients. Bone Marrow Transplant 1996; 17:101¬9.
8. Smith KA. Interleukin-2: Inception, impact, and
implications. Science 1988; 240:1169-76.
9. Gratwohl A, Hermans J, Baldomero H. Hematopoietic precursor cell transplantation in Europa: Activity in 1994. Report from the European group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 1996;
17:137-48.
10. Goldman JM. Peripheral blood stem cells for allografting. Blood 1995; 85: 1413-6.
11. Korbling M, Juttner C, Henon P, Kessinger A. Autologous blood stem cell versus bone marrow transplantation. Bone Marrow Transplant 1992; 10 (Suppl 1): 144-8.
12. Bell AJ, Figes A, Oscier DG, Hamblin TJ. Peripheral blood stem cell autografts in the treatment of lymphoid malignancies: initial experience in three patients. Br J
Haematol 1987; 66: 63-8.
13. Gribben JG, Freedman AS, Neuberg D, et al. Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. N Engl J Med
1991; 325: 1525-33.
14. Caligiuri MA, Zmuidzinas A, Manley TJ, Levine H, Smith KA, Ritz J. Functional consequences of interleukin-2 receptor expression on resting human lymphocytes: Identification of a novel natural killer cell subset with high
affinity receptors. J Exp Med 1990; 171:1509-26.
15. Farace F, Angevin E, Dietrich P-R, et al. Low-dose IL-2 treatment: Activation of discrete T- and NK-cell sub-populations in vivo. Int J Cancer 1995; 62:523-8.
16. Thatcher N, Gasiunas N, Crowther D. Lymphocyte function in the blood of patients with untreated non-Hodgkin lymphoma: Influence of stage and pathology. Med Ped
Oncol 1977; 3:311-21.
17. Noguchi S, Bukowski R, Deodhar S, Hewlett JS. T and B
lymphocytes in non-Hodgkin's lymphoma. Cancer 1976;
23:89-98.
18. Talmadge JE. The combination of stem cell transplantation and immunotherapy: Future potential. In Vivo 1994;
8(5):675-90.

Thank you for copying data from http://www.arastirmax.com